? Tumor Biology Program The Tumor Biology Program is one of two basic science Research Programs of the Abramson Cancer Center (ACC). This Program aims to catalyze research within the ACC to advance an understanding of mechanisms underlying tumorigenesis and to identify pathways that will enable novel preventive, diagnostic, prognostic and therapeutic approaches to cancer. Since its inception in the early 1970s, the Tumor Biology Program has continued to respond to emerging areas and advances in cancer research. The Program is currently organized around three central Aims: 1) Elucidate the molecular and cellular basis underlying cancer; 2) Understand the epigenetics of cancer; and 3) Investigate the tumor microenvironment and metastatic progression. Members of Tumor Biology are highly interactive, collaborating intra-Programmatically across scientific topics relevant to each Aim including genome integrity, cell signaling, metabolism, and viral pathways, with an eye on cancers of highest burden or health disparity in our catchment area. Ground-breaking discoveries in Tumor Biology uncovered novel mechanisms of epithelial-mesenchymal transition, transcriptional control of cancer drug sensitivity, epigenetic regulation of inflammation, novel mechanisms of androgen-resistance in prostate cancer, and immune evasion by viral mimicry. New targets were translated to the clinic in collaboration with other Programs for early detection and treatment. The Tumor Biology Program is led by new and energetic Program co-Leaders (PLs) Shelley Berger, PhD and Sandra Ryeom, PhD, who together catalyze impactful intra- and inter-Programmatic collaborations by a variety of innovative methods. The PLs are instrumental in recruiting new members, mentoring junior faculty, stimulating interactions and meetings among faculty members, and organizing conferences and symposia. Tumor Biology Program members play key roles in the training and mentorship of high school students, PhD students, MD/PhD students, and MD or PhD postdoctoral fellows in cancer-related research through their leadership roles in the University of Pennsylvania Biomedical Graduate Studies (BGS), MD/PhD program (MSTP) and NIH T32 training grants. The continued success of the Tumor Biology Program is evidenced by the exceptional scientific progress of its members, demonstrated through high-impact publications with multi-institutional, inter- and intra-Programmatic collaborations, offering key insights into the biology of cancer. Currently, the Program has 53 members from 20 departments and five different schools with total funding of $25.7M (annual direct costs) of which 20.0M is peer-reviewed and $6.4M is NCI-funded. The Program has 67 R01-equivalents. Since 2015, Tumor Biology Program members published 617 cancer-related papers, of which 15% were intra-Programmatic, 29% were inter-Programmatic, and 62% were multi-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088743
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Vonderheide, Robert H (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33:563-569
Romero, Sally A D; Jones, Lee; Bauml, Joshua M et al. (2018) The association between fatigue and pain symptoms and decreased physical activity after cancer. Support Care Cancer 26:3423-3430
Safo, Sandra E; Li, Shuzhao; Long, Qi (2018) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics 74:300-312
Kall, Stefanie L; Delikatny, Edward J; Lavie, Arnon (2018) Identification of a Unique Inhibitor-Binding Site on Choline Kinase ?. Biochemistry 57:1316-1325

Showing the most recent 10 out of 1047 publications